Fertility and sterility · 2011
Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study.
СтатьяРандомизированное исследованиеПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Eleanor, McCabe Elizabeth, Newton-Cheh Christopher, Bloch Kenneth, Buys Emmanuel, Wang Thomas, Miller Karen K
Аннотация
OBJECTIVE: To investigate whether testosterone administration alters natriuretic peptide levels in women.
DESIGN: Three-month, double-blind, randomized, placebo-controlled study.
SETTING: Clinical research center.
PATIENT(S): Fifty-one women with hypoandrogenemia due to hypopituitarism.
INTERVENTION(S): Transdermal testosterone (300 μg daily) or placebo patch.
MAIN OUTCOME MEASURE(S): N-Terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
RESULT(S): NT-proBNP levels decreased in the transdermal testosterone group compared with placebo over three months. The difference between groups remained significant after controlling for baseline age, systolic blood pressure, body mass index, and homeostasis model assessment of insulin resistance. Change in NT-proBNP over 3 months was inversely associated with change in free testosterone levels.
CONCLUSION(S): Testosterone administration to women results in decreased natriuretic peptide levels, suggesting that testosterone may be an inverse regulator of the natriuretic peptide system.
CLINICAL TRIALS REGISTRATION NUMBER: NCT00027430.
DESIGN: Three-month, double-blind, randomized, placebo-controlled study.
SETTING: Clinical research center.
PATIENT(S): Fifty-one women with hypoandrogenemia due to hypopituitarism.
INTERVENTION(S): Transdermal testosterone (300 μg daily) or placebo patch.
MAIN OUTCOME MEASURE(S): N-Terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
RESULT(S): NT-proBNP levels decreased in the transdermal testosterone group compared with placebo over three months. The difference between groups remained significant after controlling for baseline age, systolic blood pressure, body mass index, and homeostasis model assessment of insulin resistance. Change in NT-proBNP over 3 months was inversely associated with change in free testosterone levels.
CONCLUSION(S): Testosterone administration to women results in decreased natriuretic peptide levels, suggesting that testosterone may be an inverse regulator of the natriuretic peptide system.
CLINICAL TRIALS REGISTRATION NUMBER: NCT00027430.
Предметные рубрики MeSH
Administration, CutaneousAdultAnalysis of VarianceAndrogensBiomarkersBostonDouble-Blind MethodDown-RegulationFemaleHormone Replacement TherapyHumansHypopituitarismMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPilot ProjectsRegression AnalysisTestosteroneTime FactorsTransdermal PatchTreatment OutcomeYoung Adult